Compare Okta, Inc. (OKTA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Okta, Inc. trades at $205.99 (market cap $37.05B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Okta, Inc. is far larger — about 7.4× Travere Therapeutics Inc. Common Stock's market cap, and Okta, Inc. is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| OKTA | TVTX | |
|---|---|---|
Market Cap | $37.05B | $5.02B |
Volume | 4,638,855 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $232.13 | $67.52 |
52-Week Low | $62.93 | $26.79 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $34.80B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $226.53, showing modest daily weakness with a 0.24% decline. The stock maintains strong bullish technical momentum with consistent earnings beats and positive analyst sentiment. Recent developments include the company's AI Agent Security Blueprint Alliance announcement at Oktane 2026, positioning Okta for growth in the emerging AI security market. Fundamental improvements show revenue growth from $2.3B in 2024 to $2.6B in 2025, with the company achieving profitability after several years of losses.
Outlook remains positive with 74% analyst buy ratings and a $245 high price target, though valuation multiples appear stretched with P/E of 136. Key risks include competitive pressures in cybersecurity and the stock's premium valuation. The transition to profitability and AI security positioning provide catalysts, but investors should monitor execution against growth expectations.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
